Amneal Takes A Step Forward On Biosimilars
FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience
Executive Summary
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
You may also be interested in...
Amneal Plans ‘Meaningful Additions’ To Its Generics Portfolio
Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.
Amneal Adds Another Complex Generic With TobraDex Approval
Amneal has broadened its complex generics portfolio by gaining FDA approval for its generic version of ophthalmic combination medicine TobraDex.
Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.